- Home
- ULS vs ROIV Comparison
ULS vs ROIV Comparison
Compare ULS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- ROIV
- Stock Information
- Founded
- ULS 1894
- ROIV 2014
- Country
- ULS United States
- ROIV United Kingdom
- Employees
- ULS N/A
- ROIV N/A
- Industry
- ULS
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ULS
- ROIV Health Care
- Exchange
- ULS Nasdaq
- ROIV Nasdaq
- Market Cap
- ULS 14.6B
- ROIV 8.6B
- IPO Year
- ULS 2024
- ROIV N/A
- Fundamental
- Price
- ULS $66.76
- ROIV $14.08
- Analyst Decision
- ULS Buy
- ROIV Strong Buy
- Analyst Count
- ULS 8
- ROIV 4
- Target Price
- ULS $69.25
- ROIV $15.50
- AVG Volume (30 Days)
- ULS 813.1K
- ROIV 6.6M
- Earning Date
- ULS 11-04-2025
- ROIV 11-11-2025
- Dividend Yield
- ULS 0.78%
- ROIV N/A
- EPS Growth
- ULS 21.42
- ROIV N/A
- EPS
- ULS 1.62
- ROIV N/A
- Revenue
- ULS $2,951,000,000.00
- ROIV $23,233,000.00
- Revenue This Year
- ULS $6.69
- ROIV N/A
- Revenue Next Year
- ULS $6.24
- ROIV $281.14
- P/E Ratio
- ULS $41.28
- ROIV N/A
- Revenue Growth
- ULS 6.92
- ROIV N/A
- 52 Week Low
- ULS $48.11
- ROIV $8.73
- 52 Week High
- ULS $74.15
- ROIV $14.48
- Technical
- Relative Strength Index (RSI)
- ULS 53.06
- ROIV 76.40
- Support Level
- ULS $61.64
- ROIV $11.85
- Resistance Level
- ULS $68.43
- ROIV $14.48
- Average True Range (ATR)
- ULS 1.86
- ROIV 0.42
- MACD
- ULS 0.61
- ROIV 0.21
- Stochastic Oscillator
- ULS 75.41
- ROIV 86.26
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.